UroGen Pharma Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma or view top-rated stocks.

Wall Street analysts have given UroGen Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but UroGen Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

UroGen Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for UroGen Pharma.

UroGen Pharma Ltd. (NASDAQ:URGN) announced its earnings results on Wednesday, March, 17th. The company reported ($1.38) EPS for the quarter, missing the Zacks' consensus estimate of ($1.37) by $0.01.
View UroGen Pharma's earnings history.

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, URGN shares have decreased by 23.9% and is now trading at $18.15.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued twelve-month price targets for UroGen Pharma's shares. Their forecasts range from $26.00 to $57.00. On average, they expect UroGen Pharma's share price to reach $42.25 in the next year. This suggests a possible upside of 132.8% from the stock's current price.
View analysts' price targets for UroGen Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to UroGen Pharma include DiaMedica Therapeutics (DMCAF), Travere Therapeutics (TVTX), Zentalis Pharmaceuticals (ZNTL), Generation Bio (GBIO), Kronos Bio (KRON), uniQure (QURE), Heron Therapeutics (HRTX), ImmunoGen (IMGN), Aclaris Therapeutics (ACRS), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPD), Supernus Pharmaceuticals (SUPN), PMV Pharmaceuticals (PMVP), Cara Therapeutics (CARA) and Zymeworks (ZYME).
View all of URGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu Biopharma (AYTU).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of URGN stock can currently be purchased for approximately $18.15.

UroGen Pharma has a market capitalization of $379.28 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis.

UroGen Pharma employs 187 workers across the globe.

The official website for UroGen Pharma is www.urogen.com.

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected]